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After trypsinisation, 3D spheroids of C3A hepatocytes
need 18 days to re-establish similar levels of key
physiological functions to those seen in the liver
Krzysztof Wrzesinski and Stephen J. Fey*
The introduction of trypsinisation in the 1950’s was a paradigm shift which helped instigate cell culture.
We demonstrate here that human hepatocyte cell line HepG2–C3A needs at least 18 days after trypsinisa-
tion to re-establish key ultrastructural and physiological traits. After trypsinisation, cells start to recover
these traits at similar rates in both monolayer (2D) or spheroid (3D) growth environments. While this
development is restarted by trypsinisation of 2D cultures (typically after 5 days), recovery continues in 3D
cultures up until 15–18 days when changes in growth rate, adenylate kinase, ATP, urea and cholesterol all
suggest that spheroids undergo some type of physiological transition. Several other cell lines (e.g. Caco-2,
HT 29, MDCK, MCF-10A and HepG2 used to model the small and large intestine, kidney, breast acini and
liver respectively) are reported in the literature to exhibit very similar changes, on a similar timescale to
those reported here. These changes may thus represent a ubiquitous recovery process after trypsinisation
rather than diﬀerentiation. This would partially explain the common observation that cells grown in 3D
exhibit physiological capabilities that are closer to those seen in the intact tissue or organ.
Introduction
The cultivation of mammalian cells had its beginnings in the
studies where Roux showed in 1885 that it was possible to
keep embryonic chick cells alive in a saline solution,
i.e. in vitro.1 In 1911 Carrel showed that if cells are grown and
fed in aseptic conditions they can be grow for long periods
in vitro.2 The major breakthroughs in eukaryote cell culture
came with the race to develop a polio vaccine in the 1950’s fol-
lowing the polio epidemics of the 1940’s and 50’s. The HeLa
cell line was one of the first human cell lines isolated. It was
established from a human cervical carcinoma cell line in 1951
by Gey and his colleagues and it played an important role in
the production of polio antigens.3 Procedures were developed
to eﬃciently store cells for long periods of time using glycerol4
and liquid nitrogen.5 Phenol red was introduced into cultures
to follow their pH.6 In 1955, Eagle carried out the first systema-
tic study of the growth requirements necessary to propagate
cells in culture and developed an eﬀective combination of
salts, vitamins and serum.7,8 Hayflick and Moorhead demon-
strated that primary human fibroblasts have a finite life span
and die after a more or less defined number of divisions9
illustrating that not only organisms but also cells were mortal.
Thus the focus in classical cell culture techniques has been to
store cells, cultivate them, and ensure their vigorous growth
and propagation.
One of the key techniques is trypsinisation. Treatment of
minced tissues with the protease trypsin10,11 and/or collagen-
ase12 (or other enzymes) allows cells to be released from their
adhesion to other cells. This creates a single cell suspension
which can be diluted and divided into culture flasks for propa-
gation. Trypsinisation works by proteolytically degrading extra-
cellular matrix proteins (ECM). These proteins play crucial
roles in cell structure,13,14 function,15–17 signalling,18,19 and
gene expression.20 Trypsin treatment activates a number of
protease-activated receptors (PAR 1–4), some of which have
considerable eﬀects on gene expression. These genes have
been linked with a number of diseases including inflammatory
and proliferative disorders, and cancer progression (especially
metastasis and angiogenesis).21–23 Thus, regular trypsinisation
will prevent cells from constructing their natural structure,
disturb their advanced functions, signal transduction, gene
expression and prevent the full repair of their specific ECM.
Despite this, very little has been done to determine when the
damage caused by trypsinisation has been repaired.
In the intact organism or tissue, the vast majority of cells
are contact inhibited and remain in growth arrest (G0). Trypsi-
nisation removes this contact inhibition, causing the cells to
enter the cell cycle in an attempt to repair the ‘wound’. For
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these reasons, cells in culture cannot be thought of as equival-
ent to cells in an intact tissue or organism and there is a
growing awareness of the fact that cells cultured using tra-
ditional two dimensional (2D) cell culture techniques lack a
number of advanced physiological functions in addition to the
direct eﬀects on their structure or signalling capacity.
Conversely, cells grown in three dimensional (3D) environ-
ments (in suspension, on beads, scaﬀolds etc.) express a
number of physiological functions that resemble more closely
the native tissue in the organism than cells grown in classical
2D culture flasks or in sandwich cultures. Thus, 3D structure
has been proposed as the missing link which will provide
in vitro models that suﬃciently mimic in vivo conditions.24–26
For example, the LD50 drug response of 3D spheroids is signifi-
cantly better than cells grown in 2D, and is at least as good as
primary cells when compared to that seen in vivo.27
We have therefore examined the ability of C3A cells grown
in classical (2D) conditions or as (3D) spheroids and analysed
ultrastructure and a few key basic assays including ATP, aden-
ylate kinase, urea and cholesterol to evaluate physiological
important functions under these growth conditions. The
general activity of the cells has been monitored to ensure that
both cultures were growing well. Data has been normalized to
the amount of protein in the cells. The cells have not been
stimulated to grow or diﬀerentiate using any growth factors,
hormones or cytokines (except those naturally present in the
foetal calf serum).
Our results show that immediately following trypsinisation,
several physiologically important functions are suppressed.
Both 2D and 3D cultures start to re-establish these func-
tions at similar rates. In 2D cultures, this is usually interrupted
by trypsinisation when the cells reach confluence (after about
5 days in the conditions used here). In the 3D spheroid culture
conditions used here, it takes about 18 days to re-establish
these functions.
The biological question investigated here thus addresses
the diﬀerence of toxicity responses between cell culture and
primary tissues. The data contribute to an understanding of
the diﬀerences and will assist extrapolation of in vitro toxicity
data to clinical human responses.
Experimental
Standard culture conditions
Immortalized human hepatocytes, HepG2/C3A (ATCC
CRL-10741), were thawed from liquid nitrogen storage (from a
batch frozen after their third passage after receipt from ATCC),
and grown in standard tissue culture conditions (87.5%
D-MEM) (containing 1 g glucose per liter (Gibco Cat.
no. 31885-023); 1% Non-Essential Amino Acids (Gibco Cat.
no. 11140-035); 10% FCS (Foetal calf serum, Sigma Cat. no.
F 7524); 0.5% Penicillin/Streptomycin (Gibco Cat. no. 15140-122)
1% GlutaMAX (Gibco Cat. no. 35050-038), 37 °C, 5% CO2 95%
air). Eﬀects of storage in liquid nitrogen or thawing were elimi-
nated by growing the cells for at least three passages in tissue
culture flasks before starting the experiments, exchanging the
medium every two to three days. Cells used for experiments
were between passage number 4 and 15.
Traditional 2D cell culture
Cells were trypsinised (0.05% Trypsin/EDTA Gibco Cat. no.
15400-054) for 3 min, diluted 1 : 4 and sown out into falcon
flasks or microtitre plates and cultivated at 37 °C, 5% CO2 95%
air in a humidified incubator. The protein-based doubling
time for C3A cells grown under these conditions was 77 hours.
The cells were allowed to recover from the seeding stress and
grow for 24 h before any treatment.
Spheroid 3D cell culture
Preparation of spheroids using AggreWell™ plates. The C3A
cell spheroids were prepared using AggreWell™ 400 plates
(Stemcel Technologies Cat. no. 27845). Before use, plates were
washed twice with the standard D-MEM growth medium. All
residual air bubbles were removed from the well surface the
plates by prefilling the plates with 0.5 ml of growth medium
and centrifuging (3 min at 3000g). Cells (1.2 × 106) were added
to each well of the AggreWell™ plate, the plates were centri-
fuged (3 min at 100g) and left overnight to allow spheroid
formation.
Spheroid culture in bioreactors. The bioreactor humidity
chamber was filled with distilled sterile water, and the growth
chamber was prewetted with growth medium for 24 h before
use by rotation in the incubator (MC2 Biotek, Hørsholm Cat.
no. 010). Spheroids were detached from the AggreWell™ plates
by gently washing the wells with prewarmed pregassed growth
medium. The detached spheroids were collected into a Petri
dish and the quality of the spheroids checked by microscopy.
Spheroids were visually selected on the basis of their quality
(compactness, size and roundness) and placed into the open
bioreactors (still containing the growth media used to prewet
the bioreactor). The bioreactors were then closed. The spher-
oids were cultivated at 37 °C, 5% CO2 95% air in a humidified
incubator for a minimum of 21 days, exchanging the medium
every two to three days.27
The day when the cells were transferred into the bioreactor
is defined as day 0. An estimated 90% of the growth medium
was changed on day 1 and thereafter three times a week
during the 21 day period studied here. To achieve optimal
growth conditions for the spheroid suspension, the rotation
speed of the bioreactors was initially set between 9–11 revolu-
tions per minute (rpm) and then adjusted to compensate for
the growth of the spheroids (and reached 22–25 rpm on day
21). The population density of the spheroid population was
regulated by opening the bioreactor and ‘splitting the popu-
lation’ or removing excess spheroids (usually required between
day 6–8 and 20–22). Before samples were analysed by other
assays, spheroid batch quality was assessed by staining for
3 min with 0.4% Tryphan Blue (Gibco Cat. no. 15250-061).
Batches showing greater than 90% viability were accepted.
Culture in serum-free media. Spheroids do not grow well in
serum-free media. Therefore, for the analysis of urea and
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cholesterol production, cells and spheroids were normally
grown in standard media but this was temporarily exchanged
with serum-free media before sample collection (as described
above).
24 hours before each sampling point the standard medium
was removed and the cells/spheroids were washed twice with
Hanks solution (Gibco Cat. no. 14175-129) before the addition
of serum-free fully defined medium (98.5% UltraDOMA-PF,
Complete Protein-Free Medium, LONZA Cat. no. 12-727F, 0.5%
Penicillin/Streptomycin Gibco Cat. no. 15140-122, 1% Gluta-
MAX Gibco Cat. no. 35050-038). After sample collection at
desired time point (as given in the figures) the remaining
serum-free media was once again replaced by standard growth
medium. To minimize exposure of the spheroids to serum-free
media, parallel cultures were set up with an initiation oﬀset of
48 h. Samples were then collected alternately from each paral-
lel culture. The whole experiment was carried out in duplicate.
Electron microscopy
Cells grown in classical flat culture were grown in 75 cm2
culture flasks (TPP, Switzerland Cat. no. 90076) and grown in
standard conditions for 5 days (approximately 90% confluent).
The growth medium was removed, replaced with an equal
volume of Hank’s balanced salt solution (Gibco Cat. no.
14175-053) (HBSS) and washed by gently rocking the flask for
1 minute. The cells were then fixed as described below.
Spheroids were grown under standard conditions for
21 days and then washed by replacing the growth media with
HBSS for 15 min. After washing, cells and spheroids were fixed
with 2% glutaraldehyde in 0.1 M cacodylate buﬀer, pH 7.2 for
at least 24 h either in their microtitre plate or in the rotating
bioreactor. They were then washed in 0.1 M cacodylate buﬀer
and post-fixed in 1% OsO4 in 0.1 cacodylate buﬀer for 1 h. The
cells and spheroids were then washed in 0.1 M cacodylate
buﬀer for 5 min, in 50 mM maleate, pH 5.2 for 5 min, and
finally in 0.5% uranyl acetate in 50 mM maleate, pH 5.2 for
1 h. The samples were dehydrated through a series of increas-
ing strength ethanol solutions and transferred to propylenox-
ide and embedded in Epon. This was allowed to polymerize at
60 °C for 48 h. Ultrathin sections (40–50 nm) were cut using a
Leica Ultracut UCT ultramicrotome (Leica Mikrosystems
GmbH, Vienna, Austria) and a 45° diamond knife (Diatome
AG, Biel, Switzerland). Images were captured with a 1K Mega-
View CCD camera (Olympus SIS GmbH, Münster, Germany) in
a CM 100 transmission electron microscope (FEI, Eindhoven,
The Netherlands).
Growth rate in 2D cultures
Two diﬀerent methods were used for the determination of
growth rate of cells in monolayer cultures: the first was based
on cell counting after trypsinisation and the second was based
on determination of total amount of protein present in the
culture. Only the second procedure could be used for the
determination of growth rate of cells in the spheroids.
Growth rate based on cell number counts. Cells were trypsi-
nised, counted and inoculated into sixteen 25 cm2 cell culture
flasks (TPP, Switzerland Cat. no. 90026) at a cell density of
1.5 million cells per flask. Cells from two flasks were trypsi-
nised and counted at each experimental time point (24, 30, 48,
54, 72, 78, 96, 101 hours after inoculation). The cells were
counted using a Millipore Scepter™ cell counter (Cat. no.
PHCC00000) in triplicate.
Growth rate based on protein content. Cells were trypsi-
nised, counted and inoculated in duplicate at densities which
gave confluences corresponding to 3, 6, 12.5, 25, 50 and 75%
2 h after inoculation, when the cells had attached. The degree
of confluency was determined visually each 24 h until the wells
were more than 90% confluent. At this time they were trypsi-
nised and counted again using a Millipore Scepter™ cell
counter. The total soluble protein content was determined by
lysing the cells with lysis buﬀer (7 M Urea, Life Science Cat.
no. 821527, 2 M Thiourea: Cat. no. 88810, 2% Chaps, Cat. no.
C-3023; 0.4% DTT Cat. no. D-0632 all from Sigma-Aldrich,
0.5% Pharmalyte 3–10 and 0.5% Pharmalyte 6–11 GE Health-
care Cat. no. 17-0456-01 and 17-6001-78 respectively.28 Total
protein content was determined using the ProStain Protein
Quantification Kit (Active Motif Inc. Cat. no. 15001) modified
for use with lysis buﬀer.
Protein determination in spheroids
The amount of protein present in a sample was determined
using the fluorescence based ProStain Protein Quantification
Kit (Active Motif Inc. Cat. no. 15001) used according to the
manufacturer’s instructions modified to use together with
lysis buﬀer. In brief: all samples and standards were prepared
so that they all contained the same amount of lysis buﬀer in
the final working solution. Fluorescence was measured on
FluoStar Omega (BMG Labtech) using the following settings:
excitation filter 485 ± 12 nm; emission 590 ± 10 nm, 5 measure-
ment cycles with 10 flashes per cycle per sample. Four bio-
reactors were used per experimental condition during this
experiment. Two were sampled on day 1, 6, 13, and 21, and
other two were sampled on day 3, 10, and 15. In other words,
there were duplicate biological replicates at each time point.
Each replicate was sampled 3 times and each sample was ana-
lysed in triplicate (i.e. 2 biological replicates and 9 technical
replicates).
Growth rate and protein content estimation in spheroids
Spheroids were photographed on days 1, 3, 6, 10, 13, 15 and
21 post culture initiation and the area of on average 170 spher-
oids measured individually per time point used to calculate
the protein content of the spheroid.27 Briefly photomicro-
graphs were taken using an Olympus IX81 motorized micro-
scope equipped with UPlaneFI 10x/0.3 Ph1 ∞/− for 10×
magnification imaging, and UPlainFI 4x/0.13 PhL for 4× mag-
nification images objective lenses (Olympus), and an Olympus
DP71 camera. The spheroids have been placed in 96 well
microtitre plate with optical bottom (Nunc Cat. no. 165306)
prefilled with warm (37 °C) growth medium. Images were
transferred to the Olympus AnalySiS® Docu program (Soft
Imaging System) and the ‘shadow’ (or great circle) area of
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spheroids measured using the ‘Fitted Polygon Area’ function
which calculates the planar surface of the spheroids in μm2.
The amount of protein in spheroids was determined as
described. On this basis it could be shown that the protein
content of the spheroid could be estimated on the basis that
1 mm2 spheroid represents 16 ± 3.4 μg protein.
ATP assay
Cell viability was measured based on their ability to produce
ATP. Samples of the hepatocytes grown either in classical
culture conditions (in 96 well microtitre plates) or as spheroids
(usually 2–6 spheroids per assay point) were collected at appro-
priate times and transferred to white opaque microtitre plates
(Nunc, Cat. no. 165306), the volume of growth medium was
adjusted to 100 μl. The cells were lysed with 100 μl of lysis
buﬀer (CellTiter-Glo luminescent cell viability assay, Promega
Cat. no. G7571), shaken in the dark for 20 min before the
luminescence was measured in a FluoStar Omega® (BMG
Labtech). The following instrument parameters were used: one
kinetic window, 10 measurement cycles with 0.3 s of measure-
ments interval time, 2 s delay per measurement, additional
0.5 s delay per position change, (repeated twice for each plate
measured). Experiments were made as described in protein
determination section. The data was normalized with refer-
ence to a standard curve for ATP, to the untreated control and
to the amount of cellular protein present.
Adenylate kinase assay for cell viability
Adenylate kinase was measured using the Lonza Toxilight
assay kit (cat. no. LT07-117). Spent media from spheroid cul-
tures were collected in triplicate in connection with refreshing
the growth media (typically at 48 h intervals), diluted with five
volumes of adenylate kinase detection reagent, allowed to
incubate for five minutes and then read in a FluoStar Omega®
(BMG Labtech) using excitation wavelength of 410 ± 5 nm and
emission wavelength of 475 ± 5 nm. A standard curve was pre-
pared in the same way for each assay plate using a cell stan-
dard (4.29 million C3A cells per ml lysed in lysis buﬀer). Gain
was adjusted based on the highest standard curve values. The
data is presented as percentage dead cells, using the growth
rates determined here to calculate the number of cells and
assuming that a single cell contains 0.2 ng cellular protein.
Urea assay
Urea was measured using the Urea Assay Kit; Biovision Cat. no.
K375-100 accordingly to the manufacturer’s instruction.
Briefly, samples of growth media from duplicate cultures of
either cells or spheroids were centrifuged for 5 min at 140g to
remove any intact cellular contamination. Sixty per cent of
each supernatant was transferred into new tubes and centri-
fuged for 15 min at 14 000g to remove any cellular debris. Sixty
per cent of this supernatant was collected and used for urea
determination. 20 μl aliquots were transferred into microtitre
plates (Nunc 96-well Maxisorp plates Cat. no. 439454). Dilution
buﬀer and urease were added to the samples and incubated
for 10 min at room temperature. Thereafter the ‘Ammonia
detector solution’ was added, mixed and incubated for 15 min.
Sample fluorescence was then measured using a FluoroStar
Omega (BMG Labtech) using excitation wavelength of 410 ±
5 nm and emission wavelength of 475 ± 5 nm. A standard
curve was prepared in the same way for each assay plate using
a urea standard (Biovision Cat. no. 700623). Gain was adjusted
based on the highest standard curve values.
Cholesterol assay
Cholesterol was measured using the Amplex Red Cholesterol
Assay Kit (Invitrogen Cat. no. A12216) according to the manu-
facturer’s instruction with slight modifications. Positive, nega-
tive and standard curves were added to each reading plate.
Fifty microliter samples of media (collected as described
above) were used. Fluorescence was measured using a Fluoro-
Star Omega® (BMG Labtech) using excitation wavelength of
535 ± 5 nm and emission detection 590 ± 10 nm with tempera-
ture control set to 37 °C.
Detection of cholesterol synthesis by thin layer
chromatography
To measure cholesterol synthesis, 7 μCi ml−1 [1-14C]-sodium
acetate (Perkin Elmer Cat. no. NEC084H001MC) was added to
triplicate 2D and 3D cultures in microtitre plates and bio-
reactors and incubated for 4 h. Synthesis of labelled choles-
terol was stopped by washing the cells or spheroids three
times with 4 °C PBS (Gibco Cat. no. 14200). Samples were
treated with 10 mM NaOH for 15 min to ensure full lysis. KOH
(6% w/v) in methanol was added to the NaOH cell or spheroid
lysates, and the fatty acids in the lysates were saponified by
incubation at 60 °C for 30 minutes.29 Non-saponifiable lipids
were extracted into petroleum ether by rocking the samples for
30 minutes at 22 °C. The petroleum ether fraction was allowed
to evaporate completely at 22 °C overnight and the non-saponi-
fiable lipids were solubilized in chloroform. Samples were
loaded onto pre-dried TLC plates (SIGMA Cat. no. 99570)
alongside a [U-14C]-Cholesterol standard (GE Healthcare, Cat.
no. CFA128-50UCI). TLC was performed for 75 minutes using
freshly made petroleum ether : diethylether : acetic acid
(70% : 29.5% : 0.5%) as the mobile phase.30 Plates were dried
completely and images captured by autoradiography using
Hyperfilm MP (Amersham Cat. no. 28-9068-47). Films were
developed after 2 days exposure at room temperature. Using
the autoradiograph as a stencil, the area of silica correspond-
ing to the position of the radioactive cholesterol was scraped
oﬀ and transferred to a scintillation tube. 2.5 ml OptiPhase
Hisafe 2 (Perkin Elmer, Cat. no. 1200-436) were added to each
sample and the radioactivity present was quantitated using a
Wallac 1450 microbeta scintillation counter. The cholesterol
content of the individual samples was related to their total
protein content determined from a small sample of the NaOH
spheroid lysate.31 The data is presented as mM ATP per gram
total cellular protein, assuming that a single cell contains
0.2 ng cellular protein.
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Data analysis
Data was normalized with reference to the amount of protein
present, either determined directly when possible or by esti-
mation when direct determination was not possible.
Results
Growth rate
When grown in classical standard cell culture conditions, the
immortal C3A strain of HepG2 hepatocytes proliferate rapidly
and after 5 days reach and pass 100% confluency (Fig. 1a–c).
At this point, cultures are normally trypsinised, diluted by a
factor of 1 : 2 to 1 : 4 and sown out into fresh culture flasks
to maintain the strong growth rate. The growth environment
in the bioreactor is completely diﬀerent. Freshly formed
spheroids are small (Fig. 1d) and appear to become more
compact as they grow in size (Fig. 1e and f) acquiring a darker
centre.
The growth rate in 2D was essentially identical for all
dilutions up to about 1 : 4 and approximately constant during
the 5 days observed (Fig. 2A). At greater dilutions, the growth
rate became progressively slower. In the conditions used here,
cells grown using traditional procedures have a rapid growth
rate and have an average cell-number based doubling time
(i.e. based on the number of counted cells) of approximately
41 hours when averaged throughout the growth and trypsinisa-
tion cycle. Using only the data depicted with the filled symbols
in Fig. 2A, the protein-based doubling time in 2D culture
(i.e. based on the increase in cellular soluble protein mass)
was found to be approximately 77 h (3.2 days). This clearly
indicates that protein content of the cells is decreasing with
time (following the first approximately 24 h after trypsinisation
when cells grow but do not divide).
Due to the nature of the spheroids it was not possible to
determine the cell-number based doubling time. The protein-
based doubling time of the 3D spheroid cultures, 3 days after
initiating the cells into the bioreactor, was similar to that seen
in flat culture: approximately three days (Fig. 2B). Assuming
that there were no further changes in protein content per cell,
measurements of protein content of the spheroids indicates
that the cell proliferation rate decreased so that at 21 days the
doubling time had fallen to about 12 days.
ATP content
The total amount of ATP present per gram cellular protein in
the 2D cultures increases and then falls as the cultures reach
confluence (Fig. 2C). A linear accumulation of ATP is seen in
the 3D cultures from day 1 to 13, corresponding well to the
growth in cell numbers and showing that both cultures are
equally metabolically active at early timepoints in both 2D and
3D cultures. After this, in 3D cultures there is a clear interrup-
tion to this increase until day 18 after which the total amount
begins to increase again (Fig. 2D), at a time when cell growth
has slowed.
Adenylate kinase release
Adenylate kinase release (occurring during mitochondrial
breakdown) is often used as an early marker for apoptosis. In
2D cultures, after an initial dip, the amount of adenylate
kinase increased in proportion to the increasing cell numbers
illustrating that reaching confluence in itself is not a stimulus
for apoptosis (Fig. 2E). In the 3D cultures the amount of aden-
ylate kinase also increased in proportion to the cell number,
but only up to day 13 (Fig. 2F). After day 18 the amount fell
dramatically indicating that the diﬀerence in growth rate is not
a reflection of diﬀerences in cell survival.
Fig. 1 Light microscopy of C3A cells grown either in 2D or 3D conditions. A, B and C: ﬂat culture. C3A cells were cultivated in DMEM and when they reached
greater than 90% conﬂuency, were trypsinised and sown out into microtitre plates at 10 000 cells per well. Specimens were photographed at 1, 2 and 4 days post
trypsinisation corresponding to A sparse, B half-conﬂuent and C conﬂuent cultures. After 5 days it wound be normal to trypsinise the (conﬂuent) culture again. The
bar in A indicates 200 μm. D, E and F: spheroid culture. C3A cells were cultivated in DMEM, trypsinised and sown out into AggreWell™ plates for centrifugation. The
pellets were then left for 24 h for the cells to bond and then released into suspension culture as spheroids. These spheroids were then cultured in suspension in a
rotating bioreactor. Spheroids were photographed at 3, 6 and 17 days respectively after establishing the culture. D Three days after introduction of spheroids into
the bioreactor the cells are still loose and can be easily detached from spheroids. E After 6 days the cells have packed themselves more tightly (as seen by the darker
centre). F After 17 days it is very diﬃcult to observe changes by light microscopy. The bar in D indicates 200 μm.
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Fig. 2 Cell growth and viability. (A) Cell growth as determined in 2D cultures. Cells were counted after trypsinisation (i.e. before culture inoculation) and once
again when they had reached greater than 90% conﬂuency. Percentage conﬂuency was determined by visual inspection at 24 h intervals between inoculation and
trypsinisation. Duplicate cultures were inoculated at diﬀerent dilutions: 1 : 1.3 ◆; 1 : 2 ▲; 1 : 4 ●; 1 : 8 ■; 1 : 16.7 □; and 1 : 33.3 ○. (B) Cell growth in 3D cultures.
Spheroids were cultivated in the rotating bioreactor. Duplicate bioreactors were terminated at diﬀerent times after inoculation and the protein content of on
average 170 spheroids was estimated at each time point for each bioreactor using the relationship between their shadow area and protein content. The growth rate
was determined from the incremental increase in the total protein content of the bioreactor. (C) The total amount of ATP present in quadruplicate 2D cultures inocu-
lated at diﬀerent densities: short dash (- - -), long dash (——), and solid line (———) indicate 10 000, 15 000 and 20 000 cells per well respectively. Data was normal-
ised to mM day−1 g−1 Total cellular Protein (gTP). (D) The amount of ATP present in quadruplicate 3D cultures measured as in (C). (E) The percentage of dead cells
present in quadruplicate 2D cultures inoculated at diﬀerent densities, as estimated by adenylate kinase release with time: short dash (- - -), long dash (— —), and
solid line (———) indicate 10 000, 15 000 and 20 000 cells per well respectively. Note that the total amount of dead cells increases as the cultures reach conﬂuence.
(F) The percentage of dead cells present in quadruplicate 3D cultures, as estimated by adenylate kinase release. Error bars indicate standard deviation.
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Hepatic spheroids exhibit structural similarities to liver
Examined by electron microscopy, cells and spheroids exhibit
all the ultrastructural organelles normally seen in eukaryotic
cells (nuclei, mitochondria, rough endoplasmic reticulum, etc.
(N, M, RER respectively in Fig. 3). Both cells grown in 2D and
3D spheroids exhibit tight junctions (TJ) that compartmenta-
lize the plasma membrane, allowing diﬀerent receptors, trans-
porters and enzyme systems to be sequestered to specific
regions of the plasma membrane. However the tight junctions
are more distinct and more common in the spheroids (B and D).
In addition, spheroids exhibit several features that are in-
frequently seen when the C3A cells are grown under 2D cell
culture conditions. These features include the formation of
bile canaliculi-like structures in the microvilli-free inter-hep-
atocyte faces (Fig. 3E). In vivo, in the liver these canaliculi
merge and develop into bile ducts leading to the gall bladder.
Large numbers of microvilli can also be seen in the sinusoidal-
like channels (Fig. 3F) that in the liver in vivo, together with an
incomplete layer of endothelial cells, form the space of Disse.
Spheroids also exhibit glycogen granules characteristic for the
storage of glucose in the liver (Fig. 3G).
Urea production in immortal human hepatocytes grown either
in flat culture or as spheroids
Hepatocytes grown in either 2D or 3D produce low levels of
urea immediately after trypsinisation. When grown in 2D the
urea production is constant at about 0.7 mM per day per gram
total protein (gTP)over the course of the 5 days (Fig. 4A). In the
3D cultures, urea production starts at the same level but then
increases and more than doubles to 1.5 mM day−1 gTP−1 by
day 21 (Fig. 4B). To put this in perspective, the human liver
secretes about 25 g urea per day and this gives rise to normal
blood urea levels of 2.5 to 7.5 mM. Assuming that the liver
weighs 1.5 kg, that 75% of this weight is hepatocytes32 and
that 50% of the hepatocyte weight is protein this means that
the urea production is in the region of 0.74 mM urea day−1
gTP−1 (grams total hepatocyte protein). Human primary hep-
atocytes and HepG2 cells have been shown to produce similar
amounts of urea (0.55 mM day−1 gTP−1).33,34
Cholesterol production in immortal human hepatocytes grown
either in flat culture or as spheroids
C3A cells grown either in 2D or 3D culture showed little diﬀer-
ence in the total amount of cholesterol synthesized in the two
diﬀerent culture conditions immediately after trypsinisation
(Fig. 4C and D). In flat culture, during the next 5 days the level
of cholesterol increased dramatically from 13 to 76 mg ml−1
per milligram soluble cellular protein. Cholesterol production
in the C3A spheroids continued to increase and reached a
maximum level of over 30 μM day−1 gTP−1 at about day 16
before falling back to 22 μM day−1 gTP−1. De novo cholesterol
synthesis was confirmed by radioisotope labelling, lipid extrac-
tion and TLC analysis. Lovastatin treatment of spheroids inhi-
bits HMG-CoA reductase, the rate limiting enzyme in
cholesterol synthesis, and abolishes the cholesterol spot on
the TLC plate (Fig. 5). The average human liver synthesises
0.7–0.9 g cholesterol per day.35 Using the same logic as before
liver hepatocytes produce about 5.5 μmol day−1 gTP−1. The
levels synthesised by the spheroids is about 22 μM day−1 gTP−1
(8.5 mg day−1 gTP−1, Fig. 4D) similar to previously published
values for HepG2.36,37
Discussion
Trypsinisation of cells in culture has been a key technique
since its inception in the 1950’s. Most of the cell culture tech-
niques used currently (microscopy, flasks and microtitre
plates, plate readers and the plethora of assays associated with
them) have been optimized for working with monolayers of
cells in flat culture. To keep cells in this state, cells are
Fig. 3 Electron microscopy of C3A cells grown either in 2D or 3D conditions.
(A) and (B) Flat culture. C3A cells grown in microtitre plates for 4 days post tryp-
sinisation and then prepared for electron microscopy. The two tight junctions
(TJ) seen in A are shown at higher magniﬁcation in B. Key: N, nucleus; M, mito-
chondria; RER, rough endoplasmic reticulum. C, D, E, F and G spheroids were
grown in the bioreactor cultures for 21 days after initiation and then ﬁxed and
prepared for electron microscopy. Note the diversiﬁcation of the plasma mem-
brane into sinusoidal and lateral faces, separated by tight junctions (TJ in D), bile
canaliculi-like structures (BC in E), sinusoid-like channels packed with long micro-
villi (SC in F) and the appearance of glycogen granules (G in G). The bar in (A)
and (C) indicates 5 μM.
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regularly trypsinised, diluted and re-seeded into fresh culture
vessels and often used for assay within 24–48 h after trypsini-
sation. Despite that many studies have shown that trypsinisa-
tion disturbs ultrastructure, gene expression and physiological
functions in the cell, little work has been carried out to deter-
mine when the cells are fully recovered. If left untrypsinised,
cells attached to the bottom of the flask overgrow, form disor-
ganised multilayers leading to some of the cells having less
access to oxygen or nutrients. This is detrimental to their func-
tion and may lead to necrosis or apoptosis. If it were not for
this starvation, cells in 2D might be able to re-establish their
functionality in a similar manner to that seen for the 3D
spheroid cultures reported here. Oxygen diﬀusion is also a para-
meter limiting spheroids to a viable cell thickness of between
100–300 μm.38 Spheroids used here reach sizes of approxi-
mately 800–900 μM after 21 days in culture and a central core
of debris (presumably dead cells) is observed despite the pres-
ence of sinusoid-like and bile canalicular-like channels which
facilitate the oxygen (and nutrient) penetration through the
spheroid.
Immortal C3A hepatocytes have been cultivated in either
2D or 3D conditions and ultrastructure and a few basic physio-
logical functions investigated at various times after
trypsinisation. Two dimensional or 3D (spheroid) cultivation
gave rise to cultures in which initially the large majority of
cells were viable, possessed the normal ultrastructural orga-
nelles, had similar doubling times and produced similar
amounts of ATP, adenylate kinase, urea and cholesterol. The
amounts of urea and cholesterol increased with increasing
time in culture, illustrating that a one day old culture is signifi-
cantly diﬀerent to a four day old culture, irrespective of
whether they are grown in 2D or 3D conditions.
2D cultures grown under the conditions described here
reached confluence at day five. Such cultures would normally
be trypsinised at this stage, in accordance with the usual prac-
tice described in the literature to avoid cellular overgrowth,
despite the fact that adenylate kinase levels showed no signs
indicating apoptosis. However it has previously been shown
that ATP levels, an early indicator of apoptosis, have begun to
fall, suggesting the approach of apoptosis.39
The 3D cultures were allowed to continue to grow. At
approximately 15–18 days of culture the spheroids appeared to
undergo some form of transition, during which physiological
functions were perturbed. The growth rate went significantly
down at 16–17 days (to a doubling time of about 20 days)
before increasing again (to a doubling time of about 12 days).
Fig. 4 Urea and cholesterol production in immortal human hepatocytes grown either in ﬂat culture or as spheroids. (A) and (B) Samples of the growth media was
collected from duplicate microtitre plates (A) or bioreactors (B), clariﬁed by centrifugation and the amount of urea present quantitated at the times shown. (C) and
(D) Samples of the growth media was collected from duplicate microtitre plates (C) or bioreactors (D), clariﬁed by centrifugation and the amount of urea present
quantitated at the times shown. Data was normalized to mM or μM per day per gram total cellular protein. Error bars indicate standard deviation.
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Primary hepatocytes exhibit contact inhibition and while this
has been shown to be necessary for hepatocyte diﬀerentiation
and the establishment of important liver functions40 it is not
suﬃcient because in vitro confluent hepatocytes do not re-
establish their lost functionality before they die. The signifi-
cant reduction in growth rate of the C3A when as 3D spheroids
suggests that they are exhibiting some form of contact inhi-
bition while the increase in ATP levels illustrates that this is
not due to low metabolic activity. The amount of adenylate
kinase peaked at 17 days, and thereafter fell to low levels while
the increase in the amount of APT slowed at 13–17 days before
continuing to increase. Cholesterol synthesis peaked at 15–17
days, and urea production increased significantly after the
transition.
Diﬀerentiation in vitro
Many of the observations described here using the C3A cells
have also been seen by other authors in other systems that
acquire valuable attributes when allowed to diﬀerentiate after
reaching confluence. These systems include intestinal, kidney,
mammary epithelium and other liver cell lines from the liver.
The Human Caco-2, HT29 SW480 and SW1222 cell lines
derived from human colorectal carcinomas. They spon-
taneously diﬀerentiate into polarized absorptive cell mono-
layers which can be used for modelling intestinal compound
or drug transport.41 The enterocyte-specific enzymes expressed
by Caco-2 reach plateau of expression between weeks 2–3 and
are reliable markers to evaluate diﬀerentiation.42–44 Cell
growth rates decrease while enzyme expression specific for the
brush border increase.45 Similarly, SW1222 expressed
increased amounts of the diﬀerentiation markers CDX1 and
CK20 after 14 days.46 Lipid raft assembly of adherens junctions
takes 10 days in HT29 cells.47 Canine MDCK cells are derived
from renal tubular epithelium and are commonly used for
in vitro studies of polarised epithelial structure and function
relevant to the kidney, lung and breast. MDCK cells take 5–10
days to develop cysts which have the correct polarity when
grown on or in collagen or matrigel extracellular matrices and
the wrong polarity when grown in suspension in spinner-
flasks.48,49 Mouse mammary epithelial cells MCF-10A take
14–16 days to form mature growth-arrested acini-like spher-
oids.50,51 The human hepatocarcinoma derived cell line
HepRG needs to be grown in flat culture for 14 days to reach
confluence and can then be induced to diﬀerentiate further
towards a functional hepatocyte by growth in 2% DMSO for an
additional 14 days.52,53
Diﬀerentiation is even more common when cells are grown
in 3D cultures. Primary hepatocytes regain their ultrastruc-
ture54 and maintain their diﬀerentiated functionality.26 The
human hepatoma-derived cell line Huh7 can be used for infec-
tion with hepatitis C virus.55 C2C12 myoblasts cultured form
syncytia and express the skeletal muscle specific markers56
and 3D culture promotes stem cell diﬀerentiation.57 The pluri-
potent human embryonal carcinoma cell line NT2 can diﬀer-
entiate to dopaminergic NT2N neurons in the presence of
Sertoli cells.58 Thus the appearance of physiological functions
in cells in prolonged culture is not a new observation, and
common to them all is that they need time to recover after
trypsinisation.
Growth rate
C3A cells grown in 2D had a high growth rate and a protein-
based doubling time of about 77 hours while the cells were
non-confluent. C3A spheroids initially had the same doubling
time but during the course of the 21 days, their doubling time
fell to about 12 days. A fall in growth rate upon long term
culture has also been seen in 3D HepG2 cultures,59 Caco-243
and MCF-10A cells.51
Cellular polarization
Twenty one day-old 3D spheroids exhibited extensive tight
junctions, numerous microvilli, bile canaliculi-like structures
and glycogen granules. These significant ultrastructural diﬀer-
ences between the immature and mature cultures have been
seen before. The appearance of glycogen granules, tight junc-
tions and other ultrastructural changes 12 days after establish-
ing a confluent monolayer has been used to characterize
diﬀerentiation in Caco-2, HT29 and SW480 human colon carci-
noma cell lines41 and HepG2.60 Full structural and functional
diﬀerentiation of Caco-2 appeared to be obtained 21 days after
seeding.61 Tight junctions allow the hepatocytes in the spher-
oids to exhibit two clearly diﬀerent and specialized types of
cell faces which presumably correspond to the sinusoidal
(hepatocyte-blood interface) and inter-hepatocyte/bile
Fig. 5 Inhibition of cholesterol production by lovastatin. Triplicate spheroid cul-
tures were grown in the presence of [1-14C]-sodium acetate under various con-
ditions and non-saponiﬁable lipids (including cholesterol) were extracted and
separated on a TLC plate. (A) Cholesterol standard; (B) spheroids without radio-
isotope treatment; (C) spheroids treated with [1-14C]-sodium acetate for 1 h and
(D) spheroids were treated with 10 μM lovastatin for 30 min before the addition
of [1-14C]-sodium acetate.
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canalicular faces seen in vivo in the liver.62 Bile canaliculi and
the peroxisome system (involved in bile synthesis, secretion
and export) can be induced to diﬀerentiate in HepG2 cells by
long-term (20 days) cultivation. During this process, the RNA
and protein expression of peroxisome proliferator-activated
receptor α (PPARα) is induced by 390% and 150% respect-
ively.62 When rat hepatocytes are provided with ECM (in the
form of a sandwich culture) their polarisation and the develop-
ment of the bile canaliculi takes approximately 6 days (and
this process can be accelerated by the bile acid taurocholate).63
The division of the plasma membrane by tight junctions
allows partitioning of the various transporters which is essen-
tial to the polarization of the hepatocyte in vivo. Polarization
has been seen in diﬀerentiated Caco-2 monolayers, 14 days
after reaching confluency.64 Gene expression of the transpor-
ters PEPT1, OATPB and P-gp has been shown to more than
double during 21 day studies of the diﬀerentiation of Caco-
2 monolayers.65 While P-gp is expressed in Caco-2 from early
in the diﬀerentiation process, functional activity reached a
peak at 17 days and thereafter remained constant for the next
10 days.61,66
Cholesterol synthesis
The studies presented here show that production of cholesterol
is reduced by trypsinisation and re-establishment of choles-
terol synthesis occurs at the same rate in both 2D and 3D cul-
tures. Full recovery in 3D spheroids appears to need about
18 days. Similar results have been obtained using alginate
encapsulated HepG2.67 Since the oxidation of cholesterol is
the first step towards the production of bile acids, cholesterol
production appears to be temporally coordinated with cellular
polarization (redistribution of transporters to sinusoidal
(hepatocyte-blood interface) and inter-hepatocyte/bile canalicular
faces, ultrastructural organization of peroxisomes and the
appearance of bile canaliculi.
Cytochrome P450 expression
HepG2 cells have been shown to have low gene expression and
protein activity of the cytochromes P450 and important phase
I and II enzymes compared to freshly prepared human hepato-
cytes. However these genes are expressed and most can be up
regulated by known inducers illustrating that HepG2 has the
potential to respond.68–70 Furthermore, the gene expression of
several cytochrome P450s (1A1, 1A2, 2B6, 2D6 and 3A4) have
been shown to increase in HepG2 cells during 12 days of 3D
spheroid culture. After this increase, cytochrome 1A2 and
3A4 gene expression could be further induced by treatment
with omeprazole and rifampicin respectively.71 Re-establish-
ment of cytochrome activity would be a logical explanation for
our previous observations illustrating that the determination
of LD50 using 21 day old C3A spheroids correlated significantly
better with in vivo LD50 toxicity data for 5 common drugs than
primary hepatocytes or HepG2 cells grown in short-term 2D
culture.27
Urea secretion
HepG2 and C3A cells produce urea but surprisingly lack gene
expression for ornithine transcarbamylase and arginase I
expression (two key genes in the urea cycle). It was concluded
that the urea cycle is non-functional and that the urea is
produced by arginase II.33,72 Iyer et al. found that when C3A
cells were grown at sub-confluent 2D culture conditions the
amount of urea produced slowly declined during a 5 day
culture period.34 However, urea production was shown to
increase in C3A cells during a 10 day culture period at super-
confluent conditions and, when the correct growth media were
used, reach the same level as primary porcine hepatocytes
(increasing from 8 to 15 μmol h−1 g−1 total protein).73 These
apparently contradictory results are concordant with the data
presented here. Urea production is low in non-confluent
growth conditions and increases dramatically after the tran-
sition in long-term culture.
Propagation or proliferation
These results suggest that cells grown in 2D and 3D cultures
strive to re-establish characteristics of their in vivo state. In 2D,
this recovery process is usually interrupted by trypsinisation
when the cells reach confluence. This procedure is routine
because it becomes more diﬃcult to use many assays when
the cells begin to pile up on each other and make small clus-
ters. This gives rise to data variability when assayed by
microscopy or plate readers.
One can postulate that under the 2D growth conditions, the
cellular metabolic resources are channelled to the synthesis of
new cells – repair and proliferation – at the expense of the
diﬀerentiation process. In the absence of trypsinisation, in 3D
growth conditions, the cells finally re-establish or re-diﬀeren-
tiate. This should not be surprising: cells at the edge of a
wound should proliferate in order to repair the wound (and
single cells growing at the bottom of a culture flask must rep-
resent the most extreme form for wound where the cell has
very limited contact with any other cell). Cells in an intact
organ are growth arrested and are dedicated to carry out their
specialized functions. A similar postulate was made by Pampa-
loni et al., who compared the growth of MDCK cells grown on
2D plastic surfaces and in 3D collagen gels. They concluded
that growth on 2D surfaces favoured a tumour-like phenotype
with increased glycolysis whereas growth in 3D favoured a
diﬀerentiated polarized phenotype.74 Perhaps one should use
the terms contact growth inhibition and contact functional
activation.
Transition
Interestingly, the spheroid C3A cultures appear to go through
some form of transition. Both amount of ATP present and
adenylate kinase released was ‘disturbed’ between 13 and 18
days. After this period the amount of ATP continued to
increase while the amount of adenylate kinase per cell fell
drastically. The doubling time for cell growth was slowest at
this time, falling to 20 days during this transition before
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increasing again. The maximally observed synthesis of choles-
terol was reached in the transition at 15 days. Urea production
increased significantly thereafter. It is currently not clear what
is happening during this transition, but it is possible to postu-
late that nutrient diﬀusion (e.g. glucose and oxygen) is limiting
supplies to cells deeper in the spheroids (the spheroids are
approximately 0.87 mm in diameter). It is possible that these
cells are being forced to operate eﬃciently and resort to acti-
vating the mitochondrial oxidative phosphorylation system
which otherwise is inactive when glucose and oxygen are
plentiful (the so-called ‘Crabtree eﬀect’).75 If the spheroids are
‘circumventing’ the Crabtree eﬀect, this might in part explain
why the 3D spheroid data were superior to both 2D and to
primary hepatocytes in correlations with in vivo LD50 studies.
27
Diﬀerentiation or re-establishment
The reason why the cells need such a ‘prolonged’ period of
about 18 days to re-establish and diﬀerentiate specific func-
tions is at present unclear. Obviously there are many processes
involved: trypsinisation decreases the ability of the cell to com-
municate with its neighbours. Communication is needed to
establish the tight junctions so that cells develop their ‘polariz-
ation’ and the various pumps and transporters can be com-
partmentalized to their correct cellular interfaces, whether it is
the sinusoidal or the inter-hepatic/biliary canaliculus inter-
face. Cells round up during trypsinisation and as such will not
need so much cholesterol and this might suppress cholesterol
synthesis. Being an essential precursor, cholesterol synthesis
has to be re-established before bile acid synthesis can proceed.
The diﬀerentiation of both internal and external membranes
into microvilli, microtubular projections and peroxisomes has
to be coordinated with lipid metabolism. Complex, well-
orchestrated diﬀerentiation pathways have previously been
described for example in MDCK cyst formation.76,77
The studies presented here illustrate that it is important to
define 2D culture conditions very carefully: a 4 day old 80%
confluent culture is not the same as a 1 day old 80% confluent
culture: they will have diﬀerent metabolic capacities and diﬀer-
entially expressed enzyme systems. These enzyme systems are
in a state of flux and treatments which directly or indirectly
aﬀect them will further compound the data obtained. This
could be one of the reasons why such disparate results have
been published for the LD50 for acetaminophen (paracetamol)
using the same cell line (HepG2). In 17 diﬀerent published
studies published the LD50 values obtained varied by a factor
of more than twenty (summarized in ref. 27).
HepG2, their sub-clone C3A, and several other transformed
hepatocyte cell lines are almost invariably used in flat culture,
shortly after trypsinisation, even though there are a few reports
of their ability to recover physiological functions during pro-
longed trypsin-free culture (e.g. ref. 59). The observations pres-
ented here illustrate that C3A cells reach full metabolic
capacity (for the functions investigated here) after about
18 days. As such, all quantitative studies should be performed
with ‘re-established’ or ‘diﬀerentiated’ C3A cultures. The levels
and rates of urea, cholesterol or ATP production would then
correspond to the ‘normal’ values for this cell line.
If the results obtained here are generally true for immortal
cell lines, then care should be taken in comparing data from
cultures of diﬀerent ages and in comparisons of immortal
cells and their corresponding parental tissues. The fact that
the cells are recovering from trypsinisation and diﬀerentiating
during culture must also be taken into account when interpret-
ing the data obtained, and such data must be expected to be
only an approximation of what is actually occurring in vivo.
While cells which have been allowed to re-establish their phys-
iological functionality for at least 18 days cannot be guaran-
teed to be a flawless replica of the cell in the parental organ
in vivo, the data presented here support the proposition that
they are at least more representative. In some ways these data
echo the observation that there are diﬀerences in protein
expression in the same immortal cell line cells when grown at
diﬀerent passage numbers.78,79
Whether these changes in physiological capacity described
here are a true diﬀerentiation in culture or simply a recovery
from the eﬀects of trypsinisation is not only a semantic ques-
tion. There are a number of cell lines which develop important
physiological functionalities when they are not trypsinised for
15–20 days in culture, but there are many cell lines for which
no such data exists. If similar changes during long term
culture were found to be common for many cell types, then it
would suggest that the changes merely reflect the process of
re-establishment of cellular functions after trypsinisation. If
the changes are specific and restricted to a short list of cell
lines, then it would be more justifiable to define the develop-
ment of these changes as diﬀerentiation.
Conclusions
After trypsinisation, the human immortal hepatocyte C3A cell
line needs 18 days to re-establish several key physiological
functions. Once this recovery process is completed, these physio-
logical processes operate at levels similar to those seen
in vivo in the living organism.
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